4-氯-N-[(1-乙基吡咯烷-2-基)甲基]-2-甲氧基-5-[甲基(甲基磺酰基)氨基]苯甲酰胺 | 68256-20-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯-N-[(1-乙基吡咯烷-2-基)甲基]-2-甲氧基-5-[甲基(甲基磺酰基)氨基]苯甲酰胺
• 英文名称: Benzamide, 4-chloro-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-(methyl(methylsulfonyl)amino)-
• 英文别名: 4-chloro-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-[methyl(methylsulfonyl)amino]benzamide
• CAS: 68256-20-2
• 化学式: C₁₇H₂₆ClN₃O₄S
• 分子量: 403.93
• InChiKey: XOUZIGCMSMPFJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  87.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-氯-N-[(1-乙基吡咯烷-2-基)甲基]-2-甲氧基-5-[甲基(甲基磺酰基)氨基]苯甲酰胺 生成 4-氯-N-[(1-乙基吡咯烷-2-基)甲基]-5-(甲磺酰氨基)-2-甲氧基苯甲酰胺
  参考文献：
  名称：

  MASARU, OGATA;HIROSHI, MATSUMOTO

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯-2-甲氧基-5-硝基苯甲酸甲酯 在 platinum(IV) oxide 吡啶 、 sodium hydroxide 、 氯化亚砜 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 丙酮 为溶剂， 反应 3.17h， 生成 4-氯-N-[(1-乙基吡咯烷-2-基)甲基]-2-甲氧基-5-[甲基(甲基磺酰基)氨基]苯甲酰胺
  参考文献：
  名称：

  Synthesis and neuroleptic activity of N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-5-sulfonamidobenzamides

  摘要：

  A series of some novel N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamides involving replacement of the sulfamoyl group in sulpiride with a sulfonamido group was synthesized and tested for dopamine receptor blockade. In comparison with sulpiride, several compounds were considerably more potent than sulpiride as dopamine receptor blockers. The structure-activity relationships are discussed.

  DOI：

  10.1021/jm00375a009

文献信息

• Treatment of psychosis with meta-sulfonamido-benzamide derivatives
  申请人：Shionogi & Co., Ltd.

  公开号：US04431663A1

  公开（公告）日：1984-02-14

  Meta-sulfonamido-benzamide derivatives of the formula: ##STR1## [wherein R is a hydrogen atom or a lower alkyl, cyano, or lower alkanesulfonyl group; R.sup.1 is a lower alkyl, phenyl, amino, lower alkylamino, di(lower)alkylamino, or C.sub.4 -C.sub.5 alkyleneamino group; R.sup.2 is a hydrogen or halogen atom or a lower alkyl, di(lower)alkylamino, or lower alkoxy group; R.sup.3 is a hydrogen atom or a methyl or methoxy group; R.sup.4 is a hydrogen or halogen atom; R.sup.5 is a lower alkyl, lower alkenyl, C.sub.3 -C.sub.6 cycloalkyl, benzyl, or halogenobenzyl group; and n is 1 or zero] or their acid addition salts, showing pharmacological activity such as anti-emetic or psychotropic activity, are provided via several routes.

  提供多种途径合成药物活性为抗恶心或精神药物活性的Meta-sulfonamido-benzamide衍生物的公式：##STR1## [其中R是氢原子或较低的烷基，氰基或较低的烷基磺酰基；R.sup.1是较低的烷基，苯基，氨基，较低的烷基氨基，二（较低）烷基氨基，或C.sub.4-C.sub.5烷基氨基基团；R.sup.2是氢原子或卤原子或较低的烷基，二（较低）烷基氨基或较低的烷氧基；R.sup.3是氢原子或甲基或甲氧基；R.sup.4是氢原子或卤原子；R.sup.5是较低的烷基，较低的烯基，C.sub.3-C.sub.6环烷基，苯甲基或卤代苯甲基团；n为1或零]或它们的酸加成盐。
• Meta-sulfonamido-benzamides
  申请人：Shionogi & Co., Ltd.

  公开号：US04328155A1

  公开（公告）日：1982-05-04

  Meta-sulfonamido-benzamide derivatives of the formula: ##STR1## [wherein R is a hydrogen atom or a lower alkyl, cyano, or lower alkanesulfonyl group; R.sup.1 is a lower alkyl, phenyl, amino, lower alkylamino, di(lower)alkylamino, or C.sub.4 -C.sub.5 alkyleneamino group; R.sup.2 is a hydrogen or halogen atom or a lower alkyl, di(lower)alkylamino, or lower alkoxy group; R.sup.3 is a hydrogen atom or a methyl or methoxy group; R.sup.4 is a hydrogen or halogen atom; R.sup.5 is a lower alkyl, lower alkenyl, C.sub.3 -C.sub.6 cycloalkyl, benzyl, or halogenobenzyl group; and n is 1 or zero] or their acid addition salts, showing pharmacological activity such as anti-emetic or psychotropic activity, are provided via several routes.

  该文提供了一些Meta-磺酰氨基苯甲酰衍生物的公式：##STR1##[其中R是氢原子或较低的烷基，氰基或较低的烷基磺酰基；R.sup.1是较低的烷基，苯基，氨基，较低的烷基氨基，二（较低）烷基氨基或C.sub.4 - C.sub.5烷基氨基基；R.sup.2是氢原子或卤素原子，或较低的烷基，二（较低）烷基氨基或较低的烷氧基；R.sup.3是氢原子或甲基或甲氧基；R.sup.4是氢原子或卤素原子；R.sup.5是较低的烷基，较低的烯基，C.sub.3 - C.sub.6环烷基，苯甲基或卤代苯甲基基团；n为1或零]或它们的酸加成盐，具有抗恶心或精神活性等药理活性，并通过几种途径提供。
• Meta-amino sulfonamido-benzamides
  申请人：Shionogi & Co., Ltd.

  公开号：US04328344A1

  公开（公告）日：1982-05-04

  Meta-sulfonamido-benzamide derivatives of the formula: ##STR1## [wherein R is a hydrogen atom or a lower alkyl, cyano, or lower alkanesulfonyl group; R.sup.1 is a lower alkyl, phenyl, amino, lower alkylamino, di(lower)alkylamino, or C.sub.4 -C.sub.5 alkyleneamino group; R.sup.2 is a hydrogen or halogen atom or a lower alkyl, di(lower)alkylamino, or lower alkoxy group; R.sup.3 is a hydrogen atom or a methyl or methoxy group; R.sup.4 is a hydrogen or halogen atom; R.sup.5 is a lower alkyl, lower alkenyl, C.sub.3 -C.sub.6 cycloalkyl, benzyl, or halogenobenzyl group; and n is 1 or zero] or their acid addition salts, showing pharmacological activity such as anti-emetic or psychotropic activity, are provided via several routes.

  提供具有药理活性，例如抗恶心或精神活性的Meta-磺酰氨基苯甲酰衍生物的公式：##STR1##[其中R是氢原子或较低的烷基，氰基或较低的烷基磺酰基; R.sup.1是较低的烷基，苯基，氨基，较低烷基氨基，二（较低）烷基氨基或C.sub.4-C.sub.5烷基氨基基; R.sup.2是氢或卤原子或较低的烷基，二（较低）烷基氨基或较低的烷氧基; R.sup.3是氢原子或甲基或甲氧基; R.sup.4是氢或卤原子; R.sup.5是较低的烷基，较低烷基烯丙基，C.sub.3-C.sub.6环烷基，苯甲基或卤代苯甲基基团; n为1或零]或其酸加成盐，通过几种途径提供。
• Meta-sulfonamido-benzamide derivatives
  申请人：Shionogi & Co., Ltd.

  公开号：US04330472A1

  公开（公告）日：1982-05-18

  Meta-sulfonamido-benzamide derivatives of the formula: ##STR1## [wherein R is a hydrogen atom or a lower alkyl, cyano, or lower alkanesulfonyl group; R.sup.1 is a lower alkyl, phenyl, amino, lower alkylamino, di(lower)alkylamino, or C.sub.4 -C.sub.5 alkyleneamino group; R.sup.2 is a hydrogen or halogen atom or a lower alkyl, di(lower)alkylamino, or lower alkoxy group; R.sup.3 is a hydrogen atom or a methyl or methoxy group; R.sup.4 is a hydrogen or halogen atom; R.sup.5 is a lower alkyl, lower alkenyl, C.sub.3 -C.sub.6 cycloalkyl, benzyl, or halogenobenzyl group; and n is 1 or zero] or their acid addition salts, showing pharmacological activity such as anti-emetic or psychotropic activity, are provided via several routes.

  提供具有药理活性的Meta-sulfonamido-benzamide衍生物的公式：##STR1## [其中R是氢原子或较低烷基，氰基或较低烷基磺酰基; R.sup.1是较低烷基，苯基，氨基，较低烷基氨基，二（较低）烷基氨基或C.sub.4 -C.sub.5烷基氨基基; R.sup.2是氢原子或卤素原子或较低烷基，二（较低）烷基氨基或较低烷氧基; R.sup.3是氢原子或甲基或甲氧基; R.sup.4是氢原子或卤素原子; R.sup.5是较低烷基，较低烯基，C.sub.3 -C.sub.6环烷基，苄基或卤代苄基基团; n为1或零]或它们的酸加成盐，通过几个途径提供。
• N(2-Pyrrolidinylmethyl)meta-sulfonamido-benzamides
  申请人：Shionogi & Co., Ltd.

  公开号：US04350635A1

  公开（公告）日：1982-09-21

  Meta-sulfonamido-benzamide derivatives of the formula: ##STR1## wherein R is a hydrogen atom or a lower alkyl, cyano, or lower alkanesulfonyl group; R.sup.1 is a lower alkyl, phenyl, amino, lower alkylamino, di(lower)alkylamino, or C.sub.4 -C.sub.5 alkyleneamino group; R.sup.2 is a hydrogen or halogen atom or a lower alkyl, di(lower)alkylamino, or lower alkoxy group; R.sup.3 is a hydrogen atom or a methyl or methoxy group; R.sup.4 is a hydrogen or halogen atom; R.sup.5 is a lower alkyl, lower alkenyl, C.sub.3 -C.sub.6 cycloalkyl, benzyl, or halogenobenzyl group; and n is 1 or zero or their acid addition salts, showing pharmacological activity such as anti-emetic or psychotropic activity, are provided via several routes.

  本文介绍了一些Meta-sulfonamido-benzamide 衍生物的配方，其公式为：##STR1## 其中，R是氢原子或低碳基，氰基或低烷基磺酰基；R.sup.1是低碳基，苯基，氨基，低碳基氨基，二（低）烷基氨基或C.sub.4 -C.sub.5烷基氨基；R.sup.2是氢原子或卤素原子或低碳基，二（低）烷基氨基或低烷氧基；R.sup.3是氢原子或甲基或甲氧基；R.sup.4是氢原子或卤素原子；R.sup.5是低碳基，低烯基，C.sub.3 -C.sub.6环烷基，苯甲基或卤代苯甲基；n为1或零或它们的酸加盐。这些化合物具有药理活性，例如抗恶心或精神活性，并通过多种途径提供。